WallStreetZenWallStreetZen

NASDAQ: AUPH
Aurinia Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

AUPH past revenue growth

How has AUPH's revenue growth performed historically?
Company
30.95%
Industry
151.46%
Market
17.61%
AUPH's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AUPH's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AUPH's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

AUPH earnings and revenue history

Current Revenue
$175.5M
Current Earnings
-$78.0M
Current Profit Margin
-44.5%

AUPH Return on Equity

Current Company
-20.1%
Current Industry
-63.5%
Current Market
188%
AUPH's Return on Equity (-20.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when AUPH announces earnings.

AUPH Return on Assets

Current Company
-14.8%
Current Industry
2.9%
AUPH is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

AUPH Return on Capital Employed

Current Company
-15.86%
Current Industry
19.5%
AUPH has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AUPH vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
AUPH$175.51M-$63.05M-$78.02M+227.90%N/A
DNTH$2.83M-$43.20M-$43.56M-55.96%N/A
COGT$0.00-$188.82M-$192.41M-100.00%N/A
ARCT$166.80M-$41.52M-$29.73M+60.31%N/A
NRIX$80.89M-$130.28M-$144.73M+145.04%N/A
View Top Biotech Stocks

AUPH earnings dates

Next earnings date
May 2, 2024

Aurinia Pharmaceuticals Earnings & Revenue FAQ

What were AUPH's earnings last quarter?

On Invalid Date, Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 2023 earnings per share (EPS) of -$0.18, up 0% year over year. Total Aurinia Pharmaceuticals earnings for the quarter were -$26.88 million. In the same quarter last year, Aurinia Pharmaceuticals's earnings per share (EPS) was -$0.18.

If you're new to stock investing, here's how to buy Aurinia Pharmaceuticals stock.

What was AUPH's earnings growth in the past year?

As of Q2 2024, Aurinia Pharmaceuticals's earnings has grown year over year. Aurinia Pharmaceuticals's earnings in the past year totalled -$78.02 million.

What is AUPH's earnings date?

Aurinia Pharmaceuticals's earnings date is Invalid Date. Add AUPH to your watchlist to be reminded of AUPH's next earnings announcement.

What was AUPH's revenue last quarter?

On Invalid Date, Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 2023 revenue of $45.10 million up 58.59% year over year. In the same quarter last year, Aurinia Pharmaceuticals's revenue was $28.44 million.

What was AUPH's revenue growth in the past year?

As of Q2 2024, Aurinia Pharmaceuticals's revenue has grown 30.95% year over year. This is 120.51 percentage points lower than the US Biotechnology industry revenue growth rate of 151.46%. Aurinia Pharmaceuticals's revenue in the past year totalled $175.51 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.